The prevalence of metabolic syndrome in patients with non-alcoholic fatty liver disease in Erbil city

Maryam  Abdulwahid; Altun  Mahmood; Hussein  Yousif

doi:10.56056/amj.2024.299

Authors

Maryam Abdulwahid MBChB, Internal medicine trainee, KHCMS, Erbil Teaching Hospital
Altun Mahmood MBChB, FIBMS, Int. med., FKBMS (G&H) Gastroenterologist. Rizgary Teaching Hospital, GIT center
Hussein Yousif MBChB, DM, CABM, FRCP, Assistant professor and consultant internist, Erbil Teaching Hospital

DOI:

https://doi.org/10.56056/amj.2024.299

Keywords:

Metabolic syndrome, Non-alcoholic fatty liver disease

Abstract

Background and objectives: Non-alcoholic fatty liver disease is the accumulation of fatty units in the liver in the absence of other triggers. Its development may have been primarily caused by metabolic syndrome, so the purpose of this study is to identify the prevalence of metabolic syndrome in non-alcoholic fatty liver disease and then to discover which parameter has the strongest link with non-alcoholic fatty liver disease.

Methods: This cross-sectional study of 90 participants more than 18 years old with non-alcoholic fatty liver disease diagnosed by sonography in Erbil from August 2022 to May 2023. In each individual, metabolic syndrome criteria were taken and measured according to the National Cholesterol Education Program's Adult Treatment Panel III criteria, which were diagnosed by having three or more of these criteria, and ultrasound was used for the grading of fatty liver.

Results: Metabolic syndrome were revealed in 69 (76.67%) of the participants. A higher proportion of patients were female 51 (56.67%) and male 39 (43.33%). It revealed a statistically significant correlation between gender and metabolic syndrome, with females and males having a corresponding 44 (49%) and 25 (28%) correlation, respectively. The most frequent factor was an expanded waist circumference in 66 (73.33%) of participants, followed by triglyceride in 62 (68.89%).

Conclusion: In this study, among patients with non-alcoholic fatty liver disease significant number of the subjects had metabolic syndrome, with an increased waist circumference being the most prevalent feature, followed by high triglyceride levels, hyperglycemia, hypertension, and low high-density lipoprotein.

Downloads

Download data is not yet available.

References

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.

Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59(3):1174–97.

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-397.e10.

Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 2006;43(S1):S99–112.

Heidelbauch J, Bruderly M. Cirrhosis and Chronic Liver Failure: Part I Diagnosis and evaluation. 2006; Available from: https://repositori.uji.es/xmlui/handle/10234/187818/

Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(1):S47–64.

Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: Current and emerging. J Hepatol. 2018;68(2):362–75.

Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13(4):196–205.

Muzurovi? E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021; 119:154770.

Dobrowolski P, Prejbisz A, Kury?owicz A, Baska A, Burchardt P, Chlebus K, et al. Metabolic syndrome – a new definition and management guidelines. Arch Med Sci AMS. 2022;18(5):1133–56.

Fattahi MR, Niknam R, Safarpour A, Sepehrimanesh M, Lotfi M. The Prevalence of Metabolic Syndrome in Non-alcoholic Fatty Liver Disease; A Population-Based Study. Middle East J Dig Dis. 2016:131–7.

Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome Curr Vasc Pharmacol. 2018;16(3):219–27.

Adults NCEP. Evaluation, and Treatment of High Blood Cholesterol in. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult Treatment Panel III): Final Report. Available from: https://www.nhlbi.nih.gov/files/docs/resources/heart/atp-3-cholesterol-full-report.pdf/

Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories. JAMA. 2013;309(1):71–82.

Wall LB, Teefey SA, Middleton WD, Dahiya N, Steger-May K, Kim HM, et al. Diagnostic Performance and Reliability of Ultrasonography for Fatty Degeneration of the Rotator Cuff Muscles. J Bone Joint Surg Am. 2012;94(12):e83.

Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore). 2018;97(13): e0214.

Al-Bayati, Sabihah M; Sabbar, Rafid A. Prevalence of nonalcoholic fatty liver disease in type 2 diabetic Iraqi patients. Journal of the Arab Board of Health Specializations. 2018; 19(1): 11-8.

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.

Qassam, S.A., Ahmed Z K., Nada, SZ. The role of biochemical markers in the assessment of Non-alcoholic fatty liver disease in young Iraqi people. I Iraq Med. J. 2019; 3(2). Retrieved from https://iraqmedj.org/index.php/imj/article/view/638/

Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, et al. Nonalcoholic fatty liver disease and aging: Epidemiology to management. World J Gastroenterol WJG. 2014;20(39):14185–204.

Cameron AJ, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE. The Metabolic Syndrome in Australia: Prevalence using four definitions. Diabetes Res Clin Pract. 2007 S;77(3):471–8.

Faris M, Al-Abachi K. Prevalence of Nonalcoholic Fatty Liver Diseases Among Obese Adults in Mosul City. Pak J Med Health Sci. 2021; 15:2711–5.

Talabani BK, Rasul HH. Determination of Risk Factors and their Association with Certain Laboratory Tests of Nonalcoholic Fatty Liver Individuals in Sulaimani City/Kurdistan Region of Iraq. Univ Thi-Qar J Med. 2022;24(2):1–13.

Paudel MS, Tiwari A, Mandal A, Shrestha B, Kafle P, Chaulagai B, et al. Metabolic Syndrome in Patients with Non-alcoholic Fatty Liver Disease: A Community Based Cross-sectional study. Cureus. 2019.

Zakerkish M, Assarzadeh A, Seyedian SS, Jahanshahi A. Prevalence of Metabolic Syndrome and Related Factors in Patients with Non-alcoholic Fatty Liver. Jundishapur J Chronic Dis Care. 2022;11(1).

Patton HM, Yates K, Unalp-Arida A, Behling CA, Huang TTK, Rosenthal P, et al. Association Between Metabolic Syndrome and Liver Histology Among Children with Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2010;105(9):2093–102.